

Giuseppe Procopio

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3591872/giuseppe-procopio-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211
papers

8,145
citations

35
h-index

87
g-index

230
ext. papers

10,192
ext. citations

4.7
avg, IF

5.34
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 211 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1803-13 | 59.2 | 3725 |
| 210 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1289-1300 | 59.2 | 263 |
| 209 | Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 395-405 | 2.2 | 216 |
| 208 | Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. <i>Cancer</i> , 1999 , 86, 858-65 | 6.4 | 210 |
| 207 | Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 637-42 | 3.5 | 178 |
| 206 | Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2155-61 | 2.2 | 178 |
| 205 | CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 962-971 | 10.2 | 136 |
| 204 | 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. <i>Cancer</i> , 1998 , 83, 372-8 | 6.4 | 121 |
| 203 | Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. <i>Annals of Oncology</i> , 2011 , 22, 1812-23 | 10.3 | 109 |
| 202 | Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019 , 25, 3839-3846 | 12.9 | 90 |
| 201 | Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. <i>Annals of Oncology</i> , 2002 , 13, 614-21 | 10.3 | 85 |
| 200 | Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99 | | 71 |
| 199 | Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011 , 108, E250-7 | 5.6 | 67 |
| 198 | Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015 , 26, 2107-13 | 10.3 | 66 |
| 197 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020 , 126, 4156-4167 | 6.4 | 66 |
| 196 | Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. <i>European Urology</i> , 2013 , 64, 30-6 | 10.2 | 64 |
| 195 | Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53 | 10.2 | 62 |

| | | | |
|-----|---|------|----|
| 194 | Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. <i>British Journal of Cancer</i> , 2011 , 104, 1256-61 | 8.7 | 60 |
| 193 | Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. <i>Cancer</i> , 2006 , 107, 2474-81 | 6.4 | 59 |
| 192 | Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?. <i>Annals of Oncology</i> , 2005 , 16, 1374-80 | 10.3 | 57 |
| 191 | Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42 | 7.5 | 55 |
| 190 | Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , 2013 , 8, e83026 | 3.7 | 52 |
| 189 | Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. <i>British Journal of Cancer</i> , 2010 , 102, 80-6 | 8.7 | 52 |
| 188 | Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10 | 12.8 | 50 |
| 187 | Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 929-38 | 3.8 | 50 |
| 186 | Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100 | 3.1 | 48 |
| 185 | Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105 | 5.6 | 48 |
| 184 | Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7 | 2.5 | 43 |
| 183 | Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. <i>British Journal of Cancer</i> , 2013 , 108, 311-8 | 8.7 | 43 |
| 182 | Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015 , 136, 1-10 | 7.5 | 41 |
| 181 | Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016 , 11, e0151662 | 3.7 | 39 |
| 180 | Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83 | 3.6 | 38 |
| 179 | Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8 | 5.6 | 37 |
| 178 | Dual modulation of MCL-1 and mTOR determines the response to sunitinib. <i>Journal of Clinical Investigation</i> , 2017 , 127, 153-168 | 15.9 | 37 |
| 177 | Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , 2015 , 16, 164-70 | 3 | 36 |

| | | | |
|-----|---|------|----|
| 176 | The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. <i>BJU International</i> , 2012 , 110, 998-1003 | 5.6 | 35 |
| 175 | Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 484-8 | 3.3 | 34 |
| 174 | Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22 | 5 | 32 |
| 173 | Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1571-7 | 3.5 | 31 |
| 172 | Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. <i>Tumori</i> , 2004 , 90, 535-546 | 1.7 | 29 |
| 171 | Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. <i>Annals of Oncology</i> , 2017 , 28, 2464-2471 | 10.3 | 27 |
| 170 | Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. <i>Oncology</i> , 2007 , 73, 204-9 | 3.6 | 27 |
| 169 | Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial. <i>Cancer</i> , 2000 , 89, 763-8 | 6.4 | 27 |
| 168 | Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 43-51 | 7 | 26 |
| 167 | Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 479-82 | 2.7 | 25 |
| 166 | Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012 , 16, 464-7 | 2.5 | 25 |
| 165 | Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020 , 136, 195-203 | 7.5 | 24 |
| 164 | ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2021 , 32, 1511-1519 | 10.3 | 24 |
| 163 | Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4594-4602 | 5.6 | 23 |
| 162 | Pulmonary carcinoid tumours: indolent but not benign. <i>Oncology</i> , 2007 , 73, 162-8 | 3.6 | 23 |
| 161 | A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. <i>Cancer</i> , 2002 , 94, 299-304 | 6.4 | 23 |
| 160 | Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951 | 3.3 | 22 |
| 159 | Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013 , 24, 2967-71 | 10.3 | 21 |

| | | | |
|-----|---|-----|----|
| 158 | An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016 , 34, 236-42 | 4.3 | 20 |
| 157 | Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017 , 8, 100708-100716 | 3.3 | 20 |
| 156 | Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 319-326 | 3.2 | 20 |
| 155 | Multimodal treatment of advanced renal cancer in 2017. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 1395-1402 | 3.8 | 19 |
| 154 | Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019 , 2, 699-707 | 6.7 | 19 |
| 153 | Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy. <i>PLoS ONE</i> , 2018 , 13, e0199642 | 3.7 | 19 |
| 152 | Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5082-5082 | 2.2 | 19 |
| 151 | Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 291-298 | 3.3 | 18 |
| 150 | Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012 , 107, 1227-32 | 8.7 | 18 |
| 149 | Update on the treatment of neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 631-425 | 3.5 | 18 |
| 148 | Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 183-188 | 5.4 | 17 |
| 147 | Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497 | 5.7 | 17 |
| 146 | Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 152-61 | 3.2 | 17 |
| 145 | Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1644 | 5.3 | 17 |
| 144 | Treatment of collecting duct carcinoma: current status and future perspectives. <i>Anticancer Research</i> , 2014 , 34, 1027-30 | 2.3 | 17 |
| 143 | Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 137-41 | 3.3 | 16 |
| 142 | Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015 , 115, 764-71 | 5.6 | 16 |
| 141 | Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1631-40 | 3.5 | 16 |

| | | | |
|-----|---|------|----|
| 140 | Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 105, 52-64 | 7 | 16 |
| 139 | 252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC). <i>European Urology Supplements</i> , 2009 , 8, 183 | 0.9 | 15 |
| 138 | Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors. <i>International Journal of Biological Markers</i> , 2004 , 19, 295-304 | 2.8 | 15 |
| 137 | CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 498-498 | 2.2 | 15 |
| 136 | Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 2167-72 | 4.4 | 15 |
| 135 | Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 48-55 | 3.3 | 14 |
| 134 | Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 303-13 | 3.2 | 14 |
| 133 | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12, | 6.6 | 14 |
| 132 | Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102057 | 14.4 | 13 |
| 131 | Current Understanding of Urachal Adenocarcinoma and Management Strategy. <i>Current Oncology Reports</i> , 2020 , 22, 9 | 6.3 | 13 |
| 130 | Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e521-e523 | 3.3 | 13 |
| 129 | Renal Cancer Treatment: A Review of the Literature. <i>Tumori</i> , 2003 , 89, 476-484 | 1.7 | 13 |
| 128 | In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 309-10 | 4 | 13 |
| 127 | Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016 , 7, 40085-40094 | 3.3 | 13 |
| 126 | Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 332.e19-24 | 2.8 | 12 |
| 125 | Response to targeted therapy in urachal adenocarcinoma. <i>Rare Tumors</i> , 2014 , 6, 5529 | 1.1 | 12 |
| 124 | Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review. <i>Tumori</i> , 2006 , 92, 72-75 | 1.7 | 12 |
| 123 | Kit Protein (CD 117) and Proliferation Index (Ki-67) Evaluation in Well and Poorly Differentiated Neuroendocrine Tumors. <i>Tumori</i> , 2006 , 92, 531-535 | 1.7 | 12 |

| | | | |
|-----|--|------|----|
| 122 | Levofloxacin: update and perspectives on one of the original respiratory quinolones <i>Expert Review of Anti-Infective Therapy</i> , 2003 , 1, 371-87 | 5.5 | 12 |
| 121 | Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 197-197 | 2.2 | 12 |
| 120 | Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. <i>International Journal of Biological Markers</i> , 2004 , 19, 295-304 | 2.8 | 12 |
| 119 | Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020 , 15, 495-501 | 5 | 12 |
| 118 | Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 42-45 | 2.7 | 12 |
| 117 | Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 12 |
| 116 | Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014 , 10, 1741-50 | 3.6 | 11 |
| 115 | Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642 | 5.4 | 11 |
| 114 | Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. <i>Prostate</i> , 2019 , 79, 1683-1694 | 4.2 | 10 |
| 113 | The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 10 |
| 112 | Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101891 | 14.4 | 10 |
| 111 | Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 2881-91 | 3.6 | 10 |
| 110 | Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e735-e742 | 3.3 | 10 |
| 109 | Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 323-30 | 5.4 | 10 |
| 108 | Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90 | 3.3 | 10 |
| 107 | Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2021 , | 10.2 | 10 |
| 106 | Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 323-7 | 6.2 | 9 |
| 105 | Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10 | 2.5 | 9 |

| | | | |
|-----|---|-----|---|
| 104 | Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014 , 11, 237-49 | 4.2 | 8 |
| 103 | Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014 , 10, 1611-7 | 3.6 | 8 |
| 102 | Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy. <i>Tumori</i> , 2017 , 103, 15-21 | 1.7 | 8 |
| 101 | Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 497-510 | 4.1 | 8 |
| 100 | Role of sorafenib in renal cell carcinoma: focus on elderly patients. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1689-92 | 3.5 | 8 |
| 99 | The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , 2015 , 10, e0120427 | 3.7 | 8 |
| 98 | The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 603-611 | 3.5 | 7 |
| 97 | Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019 , 105, 3-12 | 1.7 | 7 |
| 96 | Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. <i>Canadian Urological Association Journal</i> , 2014 , 8, E121-5 | 1.2 | 7 |
| 95 | Activity of sunitinib in patients with advanced neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, 319-20; author reply 320 | 2.2 | 7 |
| 94 | Merkel Cell Carcinoma after Liver Transplantation: A Case Report. <i>Tumori</i> , 2007 , 93, 323-326 | 1.7 | 7 |
| 93 | Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018 , 14, 1347-1354 | 3.6 | 7 |
| 92 | Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21 | 2.8 | 6 |
| 91 | Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502 | 3.6 | 6 |
| 90 | Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015 , 9, 263-7 | 1.2 | 6 |
| 89 | Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014 , 10, 1361-72 | 3.6 | 6 |
| 88 | Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , 2013 , 9, 1599-607 | 3.6 | 6 |
| 87 | Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. <i>BJU International</i> , 2011 , 108, 223-7 | 5.6 | 6 |

| | | | |
|----|---|------|---|
| 86 | Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer. <i>Tumori</i> , 2001 , 87, 364-371 | 1.7 | 6 |
| 85 | Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. <i>Tumori</i> , 2014 , 100, e2-e3 | 1.7 | 6 |
| 84 | A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4502-4502 | 2.2 | 6 |
| 83 | Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma. <i>ImmunoTargets and Therapy</i> , 2020 , 9, 273-288 | 9 | 6 |
| 82 | Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. <i>Tumori</i> , 2006 , 92, 531-5 | 1.7 | 6 |
| 81 | Improved quality of life is the way to longer life. <i>Lancet Oncology, The</i> , 2016 , 17, 862-863 | 21.7 | 5 |
| 80 | Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 323-34 | 3.5 | 5 |
| 79 | Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 107-16 | 2.1 | 5 |
| 78 | First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. <i>Cancer Biology and Therapy</i> , 2014 , 15, 19-21 | 4.6 | 5 |
| 77 | Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. <i>Future Oncology</i> , 2013 , 9, 831-43 | 3.6 | 5 |
| 76 | Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1089-96 | 3.5 | 5 |
| 75 | Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012 , 13, 1001-8 | 4.6 | 5 |
| 74 | Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021 , 4, 274-281 | 6.7 | 5 |
| 73 | Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 121-125 | 2.7 | 5 |
| 72 | Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. <i>Oncology</i> , 2015 , 88, 133-8 | 3.6 | 4 |
| 71 | Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 385-391.e1 | 3.3 | 4 |
| 70 | Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology, The</i> , 2018 , 19, 281-283 | 21.7 | 4 |
| 69 | Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1107-1110 | 5.4 | 4 |

| | | | |
|----|--|------|---|
| 68 | Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017 , 17, 461-467 | 3.4 | 4 |
| 67 | Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. <i>Tumori</i> , 2012 , 98, 394-394 | 1.7 | 4 |
| 66 | Abiraterone acetate in castration-resistant prostate cancer. <i>Anti-Cancer Drugs</i> , 2012 , 23, 247-54 | 2.4 | 4 |
| 65 | Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome. <i>Tumori</i> , 2007 , 93, 201-203 | 1.7 | 4 |
| 64 | Current Treatments of Neuroendocrine Tumors Role of Biotherapy and Chemotherapy. <i>Tumori</i> , 2003 , 89, 111-116 | 1.7 | 4 |
| 63 | Advances in diagnosis and therapy of neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 371-81 | 3.5 | 4 |
| 62 | Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT. <i>Tumori</i> , 1999 , 85, 6-11 | 1.7 | 4 |
| 61 | PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 134-134 | 2.2 | 4 |
| 60 | Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. <i>Lancet Oncology, The</i> , 2020 , 21, 1538-1539 | 21.7 | 4 |
| 59 | Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma. <i>Cancers</i> , 2021 , 13, | 6.6 | 4 |
| 58 | Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021 , 13, | 6.6 | 4 |
| 57 | Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. <i>Oncology</i> , 2017 , 92, 269-275 | 3.6 | 3 |
| 56 | Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e526-e533 | 3.3 | 3 |
| 55 | Should we use combination therapy for all advanced renal cell carcinoma?. <i>Lancet Oncology, The</i> , 2019 , 20, 1331-1332 | 21.7 | 3 |
| 54 | Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 130-3 | 3.3 | 3 |
| 53 | Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. <i>Tumori</i> , 2009 , 95, 501-507 | 1.7 | 3 |
| 52 | From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , 2009 , 3, 79-87 | 4.3 | 3 |
| 51 | Everolimus in advanced solid tumors: when to start, early or late?. <i>Tumori</i> , 2014 , 100, e2-3 | 1.7 | 3 |

| | | | |
|----|--|-----|---|
| 50 | Urachal carcinoma: towards a precision medicine. <i>Translational Cancer Research</i> , 2016 , 5, S1307-S1310 | 0.3 | 3 |
| 49 | Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature. <i>Oncology Research</i> , 2011 , 19, 403-6 | 4.8 | 3 |
| 48 | Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABITUDE study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968725 | 5.4 | 3 |
| 47 | Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021 , 11, 682449 | 5.3 | 3 |
| 46 | Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. <i>Anticancer Research</i> , 2014 , 34, 2395-8 | 2.3 | 3 |
| 45 | Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?. <i>Cancer Biology and Therapy</i> , 2014 , 15, 486-8 | 4.6 | 2 |
| 44 | Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 59-68 | 3.2 | 2 |
| 43 | Butterfly and renal cell cancer: out of chaos comes order. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3083 | 2.2 | 2 |
| 42 | Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 107-11 | 3.2 | 2 |
| 41 | Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-7 | 3.5 | 2 |
| 40 | The emerging role of PARP inhibitors in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 715-726 | 3.5 | 2 |
| 39 | Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021 , 11, e434 | 5.7 | 2 |
| 38 | Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018 , 14, 2691-2699 | 3.6 | 2 |
| 37 | Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). <i>Oncology</i> , 2021 , 99, 747-755 | 3.6 | 2 |
| 36 | Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021 , 107, 542-549 | 1.7 | 1 |
| 35 | Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. <i>Tumori</i> , 2020 , 106, 406-412 | 1.7 | 1 |
| 34 | Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. <i>Tumori</i> , 2018 , 104, 388-393 | 1.7 | 1 |
| 33 | Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. <i>Future Oncology</i> , 2019 , 15, 2657-2666 ¹ | 3.6 | 1 |

| | | | |
|----|---|------|---|
| 32 | Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012 , 62, e5-6; author reply e7-8 | 10.2 | 1 |
| 31 | TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Tumori</i> , 2015 , 101, 701-3 | 1.7 | 1 |
| 30 | New Perspectives in Advanced Genitourinary Malignancies. <i>Tumori</i> , 2012 , 98, 267-269 | 1.7 | 1 |
| 29 | Complete responses in advanced renal cell carcinoma: utopia or real chance?. <i>Clinical and Experimental Nephrology</i> , 2013 , 17, 151-2 | 2.5 | 1 |
| 28 | Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report. <i>Tumori</i> , 2011 , 97, 115-118 | 1.7 | 1 |
| 27 | Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. <i>Neurological Sciences</i> , 2011 , 32 Suppl 2, S217-9 | 3.5 | 1 |
| 26 | Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. <i>Tumori</i> , 2010 , 96, 794-795 | 1.7 | 1 |
| 25 | Neoadjuvant targeted therapy in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2010 , 7, doi:10.1038/nrurol.2010.2-c1; author reply doi:10. | 5.5 | 1 |
| 24 | Neuroendocrine tumors (NETs). <i>Clinical Therapeutics</i> , 2009 , 31, 2060-1 | 3.5 | 1 |
| 23 | Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. <i>Medical Oncology</i> , 2010 , 27, 1267-8 | 3.7 | 1 |
| 22 | New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012 , 98, 267-9 | 1.7 | 1 |
| 21 | PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls. <i>Translational Oncology</i> , 2021 , 15, 101263 | 4.9 | 1 |
| 20 | GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211054302 | 3.2 | 1 |
| 19 | Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity | | 1 |
| 18 | Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211022870 | 3.2 | 1 |
| 17 | Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 261-268 | 3.8 | 1 |
| 16 | Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. <i>Tumori</i> , 2020 , 300891620915786 | 1.7 | 0 |
| 15 | Renal Cancer. <i>UNIPA Springer Series</i> , 2021 , 755-774 | 0.1 | 0 |

| | | | |
|----|--|-----|---|
| 14 | Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line Pazopanib in Metastatic reNal CELL Carcinoma (PIPELINE Study). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 621-627 | 2.7 | ○ |
| 13 | Patient associations and clinical oncology research: how much does a patient's voice really matter?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 433-440 | 2.2 | ○ |
| 12 | Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 320-320 | 2.2 | ○ |
| 11 | Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. <i>Journal of Translational Medicine</i> , 2021 , 19, 328 | 8.5 | ○ |
| 10 | Update on radioligand therapy with Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. <i>Tumori</i> , 2021 , 3008916211037732 | 1.7 | ○ |
| 9 | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 727 | 3.6 | ○ |
| 8 | Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017 , 61, 250-251 | 1.7 | |
| 7 | Predicting Molecular Models: Where Are We Going?. <i>EBioMedicine</i> , 2015 , 2, 1594-5 | 8.8 | |
| 6 | First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046 | 2.5 | |
| 5 | Multidisciplinary Approach of Prostate Cancer Patients 2017 , 281-293 | | |
| 4 | Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014 , 100, e282-e285 | 1.7 | |
| 3 | Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. <i>Global & Regional Health Technology Assessment</i> , 2018 , 2018, 228424031879073 | 0.2 | |
| 2 | Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.. <i>ESMO Open</i> , 2022 , 7, 100431 | 6 | |
| 1 | Management of advanced genitourinary tumors. <i>Tumori</i> , 2012 , 98, 264-6 | 1.7 | |